Available Trials

• Breast
• Hematology
• Leukemia
• Lung - Non-Small Cell Lung
• Lymphoma
• Multiple Myeloma
• Pancreas
• PNH
• Solid Tumor

Breast

• NEW: USOR 18042 A Phase 2, Non-Randomized, Open Label, Single Arm, Multi-Center Study Of Talazoparib For Neoadjuvant Treatment Of Germline BRCA 1/2 Mutation Patients With Early Triple-Negative Breast Cancer. (C3441020)

  Available at: Niles, Arlington Heights

  ---

• ECOG-ACRIN S1207 A Phase III, Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer.

  Available at: Niles, Arlington Heights

  ---

• ECOG-ACRIN 1131 A Randomized, Phase III Post-Operative Trial of Platinum Base Chemotherapy vs Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Therapy.

  Available at: Niles, Arlington Heights

  ---

• USOR 16128 POLARIS: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study. (A5481081)

  Available at: Niles, Arlington Heights

  ---

Hematology

• USOR 08160 PNH Registry: Primary Objective of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry will Collect Data to Evaluate Safety Data Specific to the Use of Solaris and to Characterize the Progression of PNH as well as Clinical Outcomes, Mortality and Morbidity in Solaris and Non-Solaris Treated Patients. Secondary Objective is Raising PNH Awareness in the Medical Community and Patient/Potential Patient Population. (M07-001)

  Available at: Niles, Arlington Heights

  ---

Leukemia

• AGIOS AG120-C-009 A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects 18 Years of Age and Older, with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation.

  Available at: Niles, Arlington Heights

  ---

• ECOG-ACRIN 1910 A Phase III, Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL Negative B Lineage Acute Lymphoblastic Leukemia in Adults.

  Available at: Niles, Arlington Heights

  ---

Lung - Non-Small Cell Lung

• ECOG-ACRIN-4512 A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib vs Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.

  Available at: Niles, Arlington Heights

  ---

• USOR 16156 A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer. (CA209-817)

  Available at: Niles, Arlington Heights

  ---

• USOR 16161 A Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab Versus Platinum-Doublet Chemotherapy in Early Stage NSCLC. (CA209-816)

  Available at: Niles, Arlington Heights

  ---

Lymphoma

• USOR 17093/CITADEL-205 A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Ka Inhibitor, In Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205) - INCB050465-205.

  Available at: Niles, Arlington Heights

  ---

• USOR 17041 Screening Protocol for STAR USOR 16248: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects with Diffuse Large B Cell Lymphoma. USOR 17041

  Available at: Niles, Arlington Heights

  ---

• USOR 16065 Relapsed/Refractory - A Phase 2b, Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma. (UTX-TGR-205)

  Available at: Niles, Arlington Heights

  ---

• USOR 16100 Hodgkins Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices. (CA20965)

  Available at: Niles, Arlington Heights

  ---

Multiple Myeloma

• USOR 17081 An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen. USOR 17081 (C16038) Ph4 Ixazomib+Lena & Dex MM (MM-6)

  Available at: Niles, Arlington Heights

  ---

• USOR 16035 Registry - A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - The Insight MM Study. (NSMM-5001)

  Available at: Niles, Arlington Heights

  ---

Pancreas

• NEWLY OPENED USOR 17160 / PANOVA-3: Pivotal, Randomized, Open-Label Study of Tumor Testing Fields (TTFields, 150kHz) concomitant with Gemcitabine and Nab-Paclitaxel for Front-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma (EF-27)

  Available at: Niles, Arlington Heights

  ---

• USOR 16187: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (AM0010-301) USOR 16187

  Available at: Niles, Arlington Heights

  ---

PNH

• USOR 08160 PNH Registry: Primary Objective of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry will Collect Data to Evaluate Safety Data Specific to the Use of Solaris and to Characterize the Progression of PNH as well as Clinical Outcomes, Mortality and Morbidity in Solaris and Non-Solaris Treated Patients. Secondary Objective is Raising PNH Awareness in the Medical Community and Patient/Potential Patient Population. (M07-001)

  Available at: Niles, Arlington Heights

  ---

Solid Tumor

• USOR 16041 AN OPEN-LABEL PHASE 2 MULTI-COHORT TRIAL OF NIVOLUMAB IN ADVANCED OR METASTATIC MALIGNANCIES. HOLDING. CONTACT RESEARCH FOR OPEN COHORTS. USOR 16041 (CA 209-627)

  Available at: Niles, Arlington Heights

  ---